PH26291A - Oxetanones - Google Patents

Oxetanones Download PDF

Info

Publication number
PH26291A
PH26291A PH33205A PH33205A PH26291A PH 26291 A PH26291 A PH 26291A PH 33205 A PH33205 A PH 33205A PH 33205 A PH33205 A PH 33205A PH 26291 A PH26291 A PH 26291A
Authority
PH
Philippines
Prior art keywords
pyran
tetrahydro
hexyl
hydroxy
formyl
Prior art date
Application number
PH33205A
Other languages
English (en)
Inventor
Pierre Dr Barbier
Fernand Dr Schneider
Ulrich Widmer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PH26291A publication Critical patent/PH26291A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12Beta-lactones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • C07D309/12Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30Oxygen atoms, e.g. delta-lactones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyesters Or Polycarbonates (AREA)
PH33205A 1984-12-21 1985-12-18 Oxetanones PH26291A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH610284 1984-12-21
CH393485 1985-09-12

Publications (1)

Publication Number Publication Date
PH26291A true PH26291A (en) 1992-04-10

Family

ID=25694219

Family Applications (1)

Application Number Title Priority Date Filing Date
PH33205A PH26291A (en) 1984-12-21 1985-12-18 Oxetanones

Country Status (20)

Country Link
US (2) US4931463A (fr)
EP (1) EP0185359B1 (fr)
CN (1) CN1012643B (fr)
AT (1) ATE70061T1 (fr)
AU (1) AU583569B2 (fr)
CA (1) CA1270837A (fr)
CS (1) CS262425B2 (fr)
DE (1) DE3584829D1 (fr)
DK (1) DK166724B1 (fr)
DO (1) DOP1985004386A (fr)
FI (1) FI91403C (fr)
HU (1) HU200172B (fr)
IE (1) IE58926B1 (fr)
IL (1) IL77338A (fr)
MC (1) MC1728A1 (fr)
NO (1) NO171160C (fr)
NZ (1) NZ214565A (fr)
PH (1) PH26291A (fr)
PT (1) PT81748B (fr)
ZW (1) ZW20385A1 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1328881C (fr) * 1984-12-21 1994-04-26 Pierre Barbier Procede pour la fabrication d'oxetanones
US5246960A (en) * 1984-12-21 1993-09-21 Hoffmann-La Roche Inc. Oxetanones
US4895973A (en) * 1986-08-14 1990-01-23 G. D. Searle & Company Substituted glutaric acid lactones in the treatment of hyperlipidemia
US4806564A (en) * 1987-05-26 1989-02-21 Merck & Co., Inc. Antihypercholesterolemic beta-lactones
US4816477A (en) * 1987-05-26 1989-03-28 Merck & Co., Inc. Antihypercholesterolemic β-lactones
CA2035972C (fr) * 1990-02-23 2006-07-11 Martin Karpf Procede de preparation d'oxetanones
US5260310A (en) * 1990-02-26 1993-11-09 Hoffmann-La Roche Inc. Oxetanone compounds and pharmaceutical compositions containing them
CA2098167C (fr) * 1992-06-24 2006-12-19 Dorothea Isler Aliments pour humains et animaux contenant un inhibiteur de la lipase
BR9807655A (pt) * 1997-02-05 2000-02-15 Hoffmann La Roche Uso de inibidores de lipase gastrintestinal.
ATE422359T1 (de) 1997-04-15 2009-02-15 Csir Verbindungen und pharmazeutische zusammensetzungen mit appetitunterdrückender aktivität
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
CA2358921A1 (fr) * 1999-10-29 2001-05-10 John Jason Gentry Mullins Derives d'oxetanone
EP1132389A1 (fr) 2000-03-06 2001-09-12 Vernalis Research Limited Nouveaux dérivés de l'azaindole pour le traitement de l'obésité
GB2363985B (en) * 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
BR0112800A (pt) 2000-07-28 2003-07-01 Hoffmann La Roche Utilização de um inibidor de lìpases e de um sequestrante de ácido de bìlis farmaceuticamente aceitáveis e processo para a prevenção e tratamento de enfermidades associadas com altos nìveis de colesterol de plasma
CA2417607C (fr) 2000-08-09 2008-01-29 Christine Feinle Utilisation d'inhibiteurs de lipase
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
JP4047723B2 (ja) 2000-10-16 2008-02-13 エフ.ホフマン−ラ ロシュ アーゲー インドリン誘導体、および5−ht2受容体リガンドとしてのその使用
US6392061B1 (en) * 2000-10-16 2002-05-21 Zpro Chemical, Inc. Process for making (2S, 3S, 5S) oxetanone derivatives
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
EP1347979B1 (fr) 2000-12-27 2007-08-08 F. Hoffmann-La Roche Ag Derives d'indole et leur utilisation en tant que ligands de recepteurs 5-ht2b et 5-ht2c
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
KR100621287B1 (ko) 2001-05-21 2006-09-13 에프. 호프만-라 로슈 아게 신경 펩타이드 y 수용체에 대한 리간드로서의 퀴놀린유도체
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
GB0202015D0 (en) 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
JP4216196B2 (ja) 2002-02-04 2009-01-28 エフ.ホフマン−ラ ロシュ アーゲー Npyアンタゴニストとしてのキノリン誘導体
RU2004129285A (ru) 2002-02-28 2005-10-27 Ф.Хоффманн-Ля Рош Аг (Ch) Производные тиазола в качестве антагонистов рецептора npy
US7728153B2 (en) 2002-04-17 2010-06-01 The Burnham Institute For Medical Research Method for the asymmetric synthesis of beta-lactone compounds
AU2003226370A1 (en) 2002-04-17 2003-11-03 The Burnham Institute Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation
EP1560816A1 (fr) 2002-07-05 2005-08-10 F. Hoffmann-La Roche Ag Derives de quinazoline
AU2003253364B2 (en) 2002-08-07 2007-06-07 F. Hoffmann-La Roche Ag Thiazole derivatives
NZ537979A (en) 2002-09-12 2007-08-31 Hoffmann La Roche N-substituted-1H-indol-5-propionic acid compounds as PPAR agonists useful for the treatment of diabetes
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
MXPA05005445A (es) 2002-11-25 2005-08-26 Hoffmann La Roche Derivados de indolilo.
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
WO2005005403A2 (fr) * 2003-07-15 2005-01-20 Ranbaxy Laboratories Limited Procede de preparation d'oxetan-2-ones
RU2006107444A (ru) 2003-08-12 2007-09-20 Ф.Хоффманн-Ля Рош Аг (Ch) 2-амино-5-бензоилтиазолы в качестве антагонистов npy
CA2533464A1 (fr) 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag Derives de thiazole utiles comme antagonistes de npy *
US7074822B2 (en) * 2004-02-23 2006-07-11 Solvay Pharmaceuticals Gmbh Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them
DE102004009076A1 (de) * 2004-02-23 2005-10-27 Solvay Pharmaceuticals Gmbh Alkylcarbamat-substituierte β-Lactone, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US7121355B2 (en) * 2004-09-21 2006-10-17 Cnh America Llc Bulldozer autograding system
WO2006035296A1 (fr) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Procede de preparation d'un derive d'orlistat utile comme standard de reference dans la determination de la purete d'orlistat et procede de preparation d'orlistat
AU2006243243B2 (en) 2005-05-03 2009-05-14 F. Hoffmann-La Roche Ag Tetracyclic azapyrazinoindolines as 5-HT2 ligands
EP1945635B1 (fr) 2005-08-18 2009-05-06 F.Hoffmann-La Roche Ag Derives de thiazolyle piperidine utile comme modulateurs du recepteur h3
US20090171104A1 (en) * 2005-10-05 2009-07-02 Killol Patel Process for the preparation of orlistat
WO2007062999A2 (fr) 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag Derives de indole-2-yl amide substitues en 1,5
EP1968967B1 (fr) 2005-11-30 2011-04-27 F. Hoffmann-La Roche AG Derives de 1,1-dioxo-thiomorpholinyl indolylmethanone utilises comme modulateurs des recepteurs h3
WO2007063000A1 (fr) 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag Derives de indole-2-carboxamide substitues en 5
WO2007065820A1 (fr) 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Dérivés d’amides tricycliques utiles pour le traitement de l’obésité
WO2007068620A1 (fr) 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Derives de pyrrolo[2,3-c]pyridine
JP2009519293A (ja) 2005-12-16 2009-05-14 エフ.ホフマン−ラ ロシュ アーゲー H3レセプター調節剤としてのピロロ[2,3−b]ピリジン誘導体
CA2635719A1 (fr) * 2006-01-13 2007-07-19 F. Hoffmann-La Roche Ag Derives de methanone de type cyclohexyle et piperazinyle et leur application en tant que modulateurs du recepteur h3 de l'histamine
DE602007008831D1 (de) * 2006-01-23 2010-10-14 Hoffmann La Roche Cyclohexyl-sulfonamid-derivate mit h3-rezeptoraktivität
US7432255B2 (en) 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
US7902184B2 (en) * 2006-05-30 2011-03-08 Hoffmann-La Roche Inc. Piperazinyl pyrimidine derivatives
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
SG182171A1 (en) * 2007-06-06 2012-07-30 Ranbaxy Lab Ltd Process for the preparation of orlistat
EP2183237A1 (fr) 2007-07-25 2010-05-12 F. Hoffmann-Roche AG Dérivés d'amide d'acide benzofurane- et benzo[b]thiophène-2-carboxylique et leur utilisation comme modulateurs du récepteur h3 de l'histamine
CA2704462A1 (fr) * 2007-10-31 2009-05-07 Burnham Institute For Medical Research Composes de beta-lactone
WO2010112569A1 (fr) 2009-03-31 2010-10-07 Robert Zimmermann Modulation de lipase de triglycérides d'adipose pour la prévention et le traitement d'une cachexie, d'une perte de poids et d'une atrophie musculaire et procédés de criblage s'y rapportant
US8993509B2 (en) 2009-03-31 2015-03-31 Robert Zimmerman Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
WO2011140190A1 (fr) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Tétrazolones utilisés en tant qu'inhibiteurs d'acide gras synthase (fasn)
KR102679975B1 (ko) * 2017-07-12 2024-06-28 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 지방독성 손상을 저감하기 위한 화합물
CN112079821A (zh) * 2020-09-14 2020-12-15 中山万汉制药有限公司 奥利司他与苯氨基嘧啶类化合物形成的缀合物及其制备方法与用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2478388A (en) * 1945-09-28 1949-08-09 Eastman Kodak Co beta-lactones from unsaturated aldehydes and unsaturated ketones
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
GB2023604B (en) * 1978-05-25 1982-07-28 Microbial Chem Res Found Physiologically active derivatives of esterastin and production thereof
JPS56128774A (en) * 1980-03-14 1981-10-08 Microbial Chem Res Found New physiologically active substance ebelactone and its preparation
CA1247547A (fr) * 1983-06-22 1988-12-28 Paul Hadvary Derives de leucine

Also Published As

Publication number Publication date
DK600385A (da) 1986-06-22
IE58926B1 (en) 1993-12-01
IL77338A (en) 1991-04-15
FI854797A7 (fi) 1986-06-22
CA1270837A (fr) 1990-06-26
DK600385D0 (da) 1985-12-20
ZW20385A1 (en) 1986-03-05
CS262425B2 (en) 1989-03-14
FI854797A0 (fi) 1985-12-04
NZ214565A (en) 1989-06-28
NO171160B (no) 1992-10-26
PT81748B (pt) 1988-07-29
US4931463A (en) 1990-06-05
DE3584829D1 (de) 1992-01-16
CN85108888A (zh) 1986-07-09
HUT39440A (en) 1986-09-29
ATE70061T1 (de) 1991-12-15
FI91403C (fi) 1994-06-27
EP0185359A2 (fr) 1986-06-25
AU5125985A (en) 1986-06-26
EP0185359B1 (fr) 1991-12-04
DK166724B1 (da) 1993-07-05
CN1012643B (zh) 1991-05-22
EP0185359A3 (en) 1987-08-26
HU200172B (en) 1990-04-28
IE853277L (en) 1986-06-21
AU583569B2 (en) 1989-05-04
US5175186A (en) 1992-12-29
NO855213L (no) 1986-06-23
FI91403B (fi) 1994-03-15
PT81748A (en) 1986-01-02
NO171160C (no) 1993-02-03
MC1728A1 (fr) 1986-12-15
DOP1985004386A (es) 1991-04-20

Similar Documents

Publication Publication Date Title
US4931463A (en) Oxetanones
US5246960A (en) Oxetanones
Clive et al. Total synthesis of both (+)-compactin and (+)-mevinolin. A general strategy based on the use of a special titanium reagent for dicarbonyl coupling
Rojo et al. Stereoselective synthesis of substituted γ-butyrolactones from γ-hydroxy-α, β-unsaturated phenyl sulfones
US3881017A (en) 9-Thiaprostaglandin compositions
US5990346A (en) Prostaglandins and processes for production thereof
DE2629644A1 (de) 16,16-spirocycloalkylprostaglandine und verfahren zu ihrer herstellung
US4885246A (en) Optically active carbacyclin intermediates and processes for the preparation thereof
KR950008310B1 (ko) 옥세타논의 제조방법
Domínguez et al. Flexible and stereoselective construction of polypropionate chains from enantiomerically pure γ-hydroxy-α, β-unsaturated sulfones
US4359581A (en) Process for the production of caracyclin intermediates
US4681951A (en) Bicyclo(3.3.0)octene derivatives
US5102793A (en) Stereospecific keto reduction of bicyclooctandione-carboxylic acid esters by microorganisms
USRE29469E (en) Hydroxylated 15-deoxy derivatives of 9-hydroxyl-13-trans-prostenoic acid
US5216177A (en) Method of preparing trans-3,4-disubstituted-γ-lactones
GB2270914A (en) HIV protease inhibitor compounds
US4920106A (en) Acetylenic cyclic carbonates
US4526991A (en) 2,6-Dioxa-bicyclo-[2,2,2]-octane-7-yl-acetaldehydes
US4107441A (en) Novel 16 hydroxy 15-deoxy-5-cis-prostenoic acids and esters
US4005106A (en) 3β-[(Methoxalyl)oxy]-2α-(3-oxo-1-octenyl)-5-oxo-1β-cyclopentaneheptanoic acid and process
HU192316B (en) Process for producing new carbacyclin derivatives and pharmaceutical compositions containing them
JPH03220158A (ja) 光学活性カルバサイクリン誘導体の製造方法
US3992412A (en) 2α-(2-Carboxy-2-oxoethyl)-3β-hydroxy-5-oxo-1β-cyclopentaneheptanoic acid and process
JPH0645575B2 (ja) 3―メチレン―2,6,7―三置換ビシクロ[3.3.0オクタン類
EP0084408A1 (fr) Composés du bicyclooctane, leur préparation et utilisation